Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia
Background As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive micr...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2025-07-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Accesso online: | https://jitc.bmj.com/content/13/7/e011148.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|